Delivery Order SPE2DR25D3015-SPE2DR26F4FB7
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,792.62 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $53,916.19 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was issued on October 8, 2025, with an ultimate completion date of October 9, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,601.28 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract is competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of September 22, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,729.10 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of November 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,027.62 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $4,229.34 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of December 11, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999 prime...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,830.66 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award was made on November 24, 2025, under a firm fixed-price contract type with an ultimate completion date of November 25, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $10,646.49 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which was not set-aside and was competitively awarded, was executed on June 17, 2025, with an ultimate completion date of June 18, 2025. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens with a ceiling value of $1,652.68. This competitively awarded, firm fixed price delivery order was issued on April 23, 2025, with an ultimate completion date of April 24, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order operates under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $5,863.86 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- SPE2DR25D3015Indefinite Delivery Contract
- SPE2DR25D3015-SPE2DR26F4FB7Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,697.26 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-set-aside, firm fixed-price delivery order was awarded on December 3, 2025, with an ultimate completion date of December 4, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a prime vendor agreement valued at $999.999 billion through December 2026 that provides comprehensive global pharmaceutical support to military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's substantial IDC vehicle enables it to supply a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains to customers including the Defense Health Agency and U.S. Coast Guard. This specific delivery order for insulin reflects the company's role in supplying essential diabetes medications and other specialty pharmaceuticals to support the Department of Defense's medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.7k | 12/2/25 |